249 related articles for article (PubMed ID: 28721629)
1. EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
La Rocca F; Airoldi I; Di Carlo E; Marotta P; Falco G; Simeon V; Laurenzana I; Trino S; De Luca L; Todoerti K; Villani O; Lackmann M; D'Auria F; Frassoni F; Neri A; Del Vecchio L; Musto P; Cilloni D; Caivano A
Cell Oncol (Dordr); 2017 Oct; 40(5):483-496. PubMed ID: 28721629
[TBL] [Abstract][Full Text] [Related]
2. Epha3 acts as proangiogenic factor in multiple myeloma.
Caivano A; La Rocca F; Laurenzana I; Annese T; Tamma R; Famigliari U; Simeon V; Trino S; De Luca L; Villani O; Berardi S; Basile A; Vacca A; Saglio G; Del Vecchio L; Musto P; Cilloni D
Oncotarget; 2017 May; 8(21):34298-34309. PubMed ID: 28415715
[TBL] [Abstract][Full Text] [Related]
3. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
[TBL] [Abstract][Full Text] [Related]
4. The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration.
Clifford N; Smith LM; Powell J; Gattenlöhner S; Marx A; O'Connor R
J Cell Biochem; 2008 Dec; 105(5):1250-9. PubMed ID: 18814179
[TBL] [Abstract][Full Text] [Related]
5. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
6. EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
Charmsaz S; Al-Ejeh F; Yeadon TM; Miller KJ; Smith FM; Stringer BW; Moore AS; Lee FT; Cooper LT; Stylianou C; Yarranton GT; Woronicz J; Scott AM; Lackmann M; Boyd AW
Leukemia; 2017 Aug; 31(8):1779-1787. PubMed ID: 27922598
[TBL] [Abstract][Full Text] [Related]
7. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.
Vail ME; Murone C; Tan A; Hii L; Abebe D; Janes PW; Lee FT; Baer M; Palath V; Bebbington C; Yarranton G; Llerena C; Garic S; Abramson D; Cartwright G; Scott AM; Lackmann M
Cancer Res; 2014 Aug; 74(16):4470-81. PubMed ID: 25125683
[TBL] [Abstract][Full Text] [Related]
8. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.
Raimondi L; Amodio N; Di Martino MT; Altomare E; Leotta M; Caracciolo D; Gullà A; Neri A; Taverna S; D'Aquila P; Alessandro R; Giordano A; Tagliaferri P; Tassone P
Oncotarget; 2014 May; 5(10):3039-54. PubMed ID: 24839982
[TBL] [Abstract][Full Text] [Related]
9. EphA3 contributes to tumor growth and angiogenesis in human gastric cancer cells.
Lv XY; Wang J; Huang F; Wang P; Zhou JG; Wei B; Li SH
Oncol Rep; 2018 Oct; 40(4):2408-2416. PubMed ID: 30066881
[TBL] [Abstract][Full Text] [Related]
10. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-controlled EphA3 marks a human endometrium-derived multipotent mesenchymal stromal cell that supports vascular growth.
To C; Farnsworth RH; Vail ME; Chheang C; Gargett CE; Murone C; Llerena C; Major AT; Scott AM; Janes PW; Lackmann M
PLoS One; 2014; 9(11):e112106. PubMed ID: 25420155
[TBL] [Abstract][Full Text] [Related]
12. EphA3 is induced by CD28 and IGF-1 and regulates cell adhesion.
Smith LM; Walsh PT; Rüdiger T; Cotter TG; Mc Carthy TV; Marx A; O'Connor R
Exp Cell Res; 2004 Jan; 292(2):295-303. PubMed ID: 14697337
[TBL] [Abstract][Full Text] [Related]
13. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
[TBL] [Abstract][Full Text] [Related]
14. ANKHD1 represses p21 (WAF1/CIP1) promoter and promotes multiple myeloma cell growth.
Dhyani A; Machado-Neto JA; Favaro P; Saad ST
Eur J Cancer; 2015 Jan; 51(2):252-9. PubMed ID: 25483783
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.
Martin SK; Diamond P; Williams SA; To LB; Peet DJ; Fujii N; Gronthos S; Harris AL; Zannettino AC
Haematologica; 2010 May; 95(5):776-84. PubMed ID: 20015878
[TBL] [Abstract][Full Text] [Related]
16. miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma.
Yang Y; Li F; Saha MN; Abdi J; Qiu L; Chang H
Clin Cancer Res; 2015 May; 21(10):2399-411. PubMed ID: 25724519
[TBL] [Abstract][Full Text] [Related]
17. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma.
Li S; Fu J; Lu C; Mapara MY; Raza S; Hengst U; Lentzsch S
Mol Cancer Ther; 2016 Apr; 15(4):711-9. PubMed ID: 26939700
[TBL] [Abstract][Full Text] [Related]
18. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
[TBL] [Abstract][Full Text] [Related]
19. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
20. Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
Wu KD; Zhou L; Burtrum D; Ludwig DL; Moore MA
Cancer Immunol Immunother; 2007 Mar; 56(3):343-57. PubMed ID: 16832681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
